$26.11
3.72% yesterday
Nasdaq, Nov 20, 10:00 pm CET
ISIN
US8808811074
Symbol
TERN

Terns Pharmaceuticals Inc Stock price

$26.11
+17.49 202.90% 1M
+22.96 728.89% 6M
+20.57 371.30% YTD
+20.51 366.25% 1Y
+20.67 379.96% 3Y
+9.11 53.59% 5Y
+9.11 53.59% 10Y
+9.11 53.59% 20Y
Nasdaq, Closing price Thu, Nov 20 2025
-1.01 3.72%
ISIN
US8808811074
Symbol
TERN
Industry

Key metrics

Basic
Market capitalization
$2.4b
Enterprise Value
$2.1b
Net debt
positive
Cash
$295.6m
Shares outstanding
87.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
8.6
Financial Health
Equity Ratio
95.0%
Return on Equity
-25.7%
ROCE
-37.9%
ROIC
-5,105.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-108.8m | $-115.1m
EBIT
$-108.5m | $-117.9m
Net Income
$-94.4m | $-100.7m
Free Cash Flow
$-78.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-9.0% | -13.3%
EBIT
-7.9% | -15.7%
Net Income
-6.8% | -13.3%
Free Cash Flow
-5.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.0
FCF per Share
$-0.9
Short interest
12.2%
Employees
59
Rev per Employee
$0.0
Show more

Is Terns Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Terns Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Terns Pharmaceuticals Inc forecast:

14x Buy
82%
3x Hold
18%

Analyst Opinions

17 Analysts have issued a Terns Pharmaceuticals Inc forecast:

Buy
82%
Hold
18%

Financial data from Terns Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
3% 3%
-
- Research and Development Expense 77 77
11% 11%
-
-109 -109
9% 9%
-
- Depreciation and Amortization -0.28 -0.28
137% 137%
-
EBIT (Operating Income) EBIT -108 -108
8% 8%
-
Net Profit -94 -94
7% 7%
-

In millions USD.

Don't miss a Thing! We will send you all news about Terns Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Terns Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
6 days ago
FOSTER CITY, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be presenting at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 4:30 p.m.
Neutral
GlobeNewsWire
10 days ago
Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract  Upcoming ASH oral presentation to feature expanded and updated dataset from CARDINAL trial Cash, cash equivalents and marketable securities of $295 million, expected to provide runway into 2028 FOSTER CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc....
Neutral
GlobeNewsWire
16 days ago
FOSTER CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of November 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Commi...
More Terns Pharmaceuticals Inc News

Company Profile

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Head office United States
CEO Amy Burroughs
Employees 59
Founded 2017
Website ternspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today